NEWS RELEASEEDITFORCE AND MITSUBISHI TANABE PHARMA ENTER INTO
LICENSE AGREEMENT

June 27, 2022
EditForce, Inc. (Headquarters: Fukuoka, President and CEO: Takashi Ono; hereinafter“EditForce”) has entered into a License Agreement (hereinafter “Agreement”) withMitsubishi Tanabe Pharma Corporation (Headquarters: Osaka, Representative Director,Hiroaki Ueno; hereinafter “MTPC”) to research, develop and commercialize potential genetherapy products for a specific target disease in the field of CNS by utilizing EditForce’s
proprietary PPR protein platform technology.
In this alliance, MTPC and EditForce aim to create potential novel pharmaceuticals for thespecific CNS disease by utilizing the drug R&D know-how and global business experienceof MTPC and the novel biotechnology of EditForce. MTPC will acquire the exclusive rightto conduct the selection of drug candidate molecules, preclinical and clinical development,manufacturing, and commercialization worldwide.
Under the terms of the Agreement, EditForce will receive an upfront payment and milestone
payments amounting to over ¥20 billion depending on the development stage andcommercialization progress, and royalties based on the worldwide sales after the launch.
“I am so delighted to reach the agreement with MTPC, which has an interest in ourproprietary PPR protein platform technology,” said Takashi Ono, President and CEO of
EditForce. “We look forward to working closely with MTPC to develop and deliver
breakthrough pharmaceutical products with our technology to patients suffering fromdiseases.”
EditForce will proceed with R&D of pharmaceuticals using our PPR protein platformtechnology.

About EditForce:
EditForce, Inc., a Kyushu University-originated venture company developing a unique
DNA/RNA editing technology (PPR platform technology*) was established in May 2015 byKISCO Co., Ltd. and Prof. Takahiro Nakamura of Kyushu University (former president ofEditForce and currently its scientific advisor) and funded by companies and funds that havetrack records of investing in life sciences and biotechnology. EditForce aims for drug
discovery that applies the PPR technology through joint research with universities andprivate companies.
For more information, please visit https://www.editforce.co.jp/*Pentatricopeptide repeat (PPR) protein platform technology
PPR is a protein discovered in plants that regulates gene expression by binding to DNA
and RNA in a sequence-specific manner. The PPR proteins are also found in humans
and yeasts, and they have similar functions. Professor Takahiro Nakamura and Dr.
Yusuke Yagi, CTO of EditForce, have focused on the PPR proteins and elucidated themechanism that determines sequence specificity, and established a technology forcreating various PPR proteins, each of which binds to a specific target DNA or RNA
sequence. Furthermore, it is possible to manipulate and modify the target genome andRNA both inside and outside the cell by fusion with effector proteins.

About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi ChemicalHoldings Group (MCHC Group), is one of the oldest pharmaceutical companies in the world,founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in
Doshomachi, Osaka, the birthplace of Japan’s pharmaceutical industry. The MCHC Grouphas positioned health care as its strategic focus in its management policy, “Forging thefuture”. MTPC sets the MISSION of “Creating hope for all facing illness”. To that end, MTPC
is prioritizing work on “precision medicine” to provide drugs with high treatment satisfaction
by identifying patient populations with high potential for efficacy and safety, focusing on thedisease areas of central nervous system and immuno-inflammation. In addition, MTPC isworking to develop “around the pill solutions” to address specific patient concerns based ontherapeutic medicine, including prevention of diseases, pre-symptomatic disease care,prevention of aggravation and prognosis.
For more information, go to https://www.mt-pharma.co.jp/e/